Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset. Issue 2 (20th December 2021)

• Record Type: Journal Article
• Authors: Wang, Huan; Xiao, Youchao; Ren, Xingguang; Wan, Dahai
• Is Part Of: Bioengineered. Volume 12:Issue 2(2021)
• Page Start: 10366
• Page End: 10378
• Publication Date: 2021-12-20
• Subjects: Glioblastoma -- immunotherapy -- isocitrate dehydrogenase -- prognostic value -- programmed death ligand 1; Biomedical engineering -- Periodicals; Biotechnology -- Periodicals; Microbiology -- Periodicals; 660.6
• DOI: 10.1080/21655979.2021.1996515
• Languages: English
• ISSNs: 2165-5987

Abstract

ABSTRACT: Excellent prognostic value of programmed death ligand 1 (PD-L1) is observed in patients with other cancers; however, the prognostic value of PD-L1 in glioblastoma (GBM) remains unclear. Therefore, this meta-analysis evaluated the prognostic value of PD-L1 in GBM. We performed a systematic search in databases to screen eligible articles. The hazard ratio (HR) and 95% confidence interval (95% CI) were extracted from included articles. This meta-analysis included 15 studies, and the forest plot indicated that increased PD-L1 expression was associated with poorer overall survival (OS) of GBM (HR, 1.16; 95% CI, 1.05–1.27; P = 0.002). Furthermore, stratified analysis confirmed that PD-L1 expression was associated with unfavorable OS at the protein level (HR, 1.30; 95% CI, 1.13–1.48; P < 0.001) and messenger ribonucleic acid (mRNA) level (HR, 1.05; 95% CI, 1.00–1.09; P = 0.041). The analysis of a dataset verified the prognostic value of PD-L1 and revealed an association between PD-L1 mRNA expression and the status of isocitrate dehydrogenase (IDH). In conclusion, increased PD-L1 expression predicts unfavorable OS in GBM and may be a promising prognostic biomarker of GBM.